Reference
1. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic
leukemia: a report from the 2nd International JMML Symposium. Leuk
Res. 2009;33(3):355-362.
2. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell
transplantation (HSCT) in children with juvenile myelomonocytic leukemia
(JMML): results of the EWOG-MDS/EBMT trial. Blood.2005;105(1):410-419.
3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the
World Health Organization classification of myeloid neoplasms and acute
leukemia. Blood. 2016;127(20):2391-2405.
4. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause
developmental abnormalities and predispose to juvenile myelomonocytic
leukemia. Nat Genet. 2010;42(9):794-800.
5. Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic
leukemia. Blood. 2015;125(7):1083-1090.
6. Matsuda K, Taira C, Sakashita K, et al. Long-term survival after
nonintensive chemotherapy in some juvenile myelomonocytic leukemia
patients with CBL mutations, and the possible presence of healthy
persons with the mutations. Blood. 2010;115(26):5429-5431.
7. Muraoka M, Okuma C, Kanamitsu K, et al. Adults with germline CBL
mutation complicated with juvenile myelomonocytic leukemia at infancy.J Hum Genet. 2016;61(6):523-526.
8. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
interpretation of sequence variants: a joint consensus recommendation of
the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet Med.2015;17(5):405-424.
9. Rosenberg HK, Markowitz RI, Kolberg H, Park C, Hubbard A, Bellah RD.
Normal splenic size in infants and children: sonographic measurements.AJR Am J Roentgenol. 1991;157(1):119-121.
10. Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of
interpretations of clinically relevant variants. Nucleic Acids
Res. 2016;44(D1):D862-868.
11. Niemeyer CM, Loh ML, Cseh A, et al. Criteria for evaluating response
and outcome in clinical trials for children with juvenile myelomonocytic
leukemia. Haematologica. 2015;100(1):17-22.
12. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem
cell transplantation treatment of juvenile myelomonocytic leukemia: A
retrospective analysis and definition of response criteria.Pediatric Blood & Cancer. 2007;49(5):629-633.
13. Martinelli S, De Luca A, Stellacci E, et al. Heterozygous germline
mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like
phenotype. Am J Hum Genet. 2010;87(2):250-257.
14. Cortellazzo Wiel L, Pastore S, Taddio A, Tommasini A. A Case of
Uveitis in a Patient With Juvenile Myelomonocytic Leukemia Successfully
Treated With Adalimumab. J Pediatr Hematol Oncol. 2019.
15. Chang TY, Dvorak CC, Loh ML. Bedside to bench in juvenile
myelomonocytic leukemia: insights into leukemogenesis from a rare
pediatric leukemia. Blood. 2014;124(16):2487-2497.
16. Tung N, Lin NU, Kidd J, et al. Frequency of Germline Mutations in 25
Cancer Susceptibility Genes in a Sequential Series of Patients With
Breast Cancer. J Clin Oncol. 2016;34(13):1460-1468.